The understanding of immune biology and the development of a newer generation of immunotherapies have opened a new stage to combat many diseases, including cancer, autoimmune, and infectious diseases. Moreover, the principal focus of the therapy is to modulate the host immune response using antibodies, vaccines, cytokines, and cellular therapies. However, it is important to note that the immune response is dynamic and constantly developing. Response to immunotherapy varies across patients, which includes the patient’s pathophysiological environment, metabolism, and genetic factors. Besides, Advanced Cell Therapeutics (ACT) are becoming more demanding for treating all kinds of diseases, including cancer, infectious diseases, , and autoimmune diseases. Few generations of CAR-T cells have been developed, and efforts are being made to advance them further in other types of cells, including NK cells, myeloid cells such as neutrophils and macrophages, as well as the use of mesenchymal stem cells to fight against all kinds of diseases and to overcome the challenges of resistances. Moreover, there are several obstacles that remain to be elucidated, such as intrinsic individual specificities, cell survival in vivo, off-targeting, cytokine release syndrome, migration to the tumor site, and the best source of cells depending on the disease.
The patient's body immune dynamic, environmental, and genetic factors lead to the development of resistance against all kinds of immunotherapeutics. A detailed study of these factors can contribute to improving ongoing therapeutic strategies, as well as substantial new developments towards tackling resistance. On the other hand, further improvements in CAR generations and engineering adaptive cells, including the release of transgenic therapeutics, and the use of checkpoint inhibitors/cytokines, will remain attractive in advancing these ACT. Therefore, in this Research Topic, we will gather manuscripts regarding all the factors causing resistance against known immunotherapeutic molecules and advancements in adaptive cellular therapeutics.
In this Research Topic, we invite authors to submit original research articles, reviews, and systematic reviews that contribute to the fields of immune therapeutics resistance and advancing ACT. We welcome submissions related to, but not limited to, the following sub-themes:
• Key factors responsible for immunotherapies resistances
• Modification of the current immunotherapy molecules.
• Modification of the Chimeric antigen receptor
• Modification and use of other immune cells such as NK, neutrophils, macrophage etc. with respect to targeting different diseases and releasing novel therapeutic molecules.
• Obstacle in the modifying and use of all immune cells
• In silico models of immunotherapy resistance mechanisms
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
The understanding of immune biology and the development of a newer generation of immunotherapies have opened a new stage to combat many diseases, including cancer, autoimmune, and infectious diseases. Moreover, the principal focus of the therapy is to modulate the host immune response using antibodies, vaccines, cytokines, and cellular therapies. However, it is important to note that the immune response is dynamic and constantly developing. Response to immunotherapy varies across patients, which includes the patient’s pathophysiological environment, metabolism, and genetic factors. Besides, Advanced Cell Therapeutics (ACT) are becoming more demanding for treating all kinds of diseases, including cancer, infectious diseases, , and autoimmune diseases. Few generations of CAR-T cells have been developed, and efforts are being made to advance them further in other types of cells, including NK cells, myeloid cells such as neutrophils and macrophages, as well as the use of mesenchymal stem cells to fight against all kinds of diseases and to overcome the challenges of resistances. Moreover, there are several obstacles that remain to be elucidated, such as intrinsic individual specificities, cell survival in vivo, off-targeting, cytokine release syndrome, migration to the tumor site, and the best source of cells depending on the disease.
The patient's body immune dynamic, environmental, and genetic factors lead to the development of resistance against all kinds of immunotherapeutics. A detailed study of these factors can contribute to improving ongoing therapeutic strategies, as well as substantial new developments towards tackling resistance. On the other hand, further improvements in CAR generations and engineering adaptive cells, including the release of transgenic therapeutics, and the use of checkpoint inhibitors/cytokines, will remain attractive in advancing these ACT. Therefore, in this Research Topic, we will gather manuscripts regarding all the factors causing resistance against known immunotherapeutic molecules and advancements in adaptive cellular therapeutics.
In this Research Topic, we invite authors to submit original research articles, reviews, and systematic reviews that contribute to the fields of immune therapeutics resistance and advancing ACT. We welcome submissions related to, but not limited to, the following sub-themes:
• Key factors responsible for immunotherapies resistances
• Modification of the current immunotherapy molecules.
• Modification of the Chimeric antigen receptor
• Modification and use of other immune cells such as NK, neutrophils, macrophage etc. with respect to targeting different diseases and releasing novel therapeutic molecules.
• Obstacle in the modifying and use of all immune cells
• In silico models of immunotherapy resistance mechanisms
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.